Divyansu Patel, MD
Psychiatry · Austin, TXNPI 1710178702
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 45 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 29.6% of the total. Reporting peaked in 2019 at $29,270 and has fallen 94.0% since, to $1,765 in 2025. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,321 payments — averaging $37.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$15K
- Ironshore Pharmaceuticals Inc.$12K
- Johnson & Johnson$4K
- Alkermes, Inc.$2K
- Neos Therapeutics, LP$2K
- AbbVie$1K
- plus $13K from 39 others
Across 688 payments — averaging $4197.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$776K
- Janssen Research & Development, LLC$562K
- Sage Therapeutics, LLC$500K
- Genentech, Inc.$285K
- Supernus Pharmaceuticals, Inc.$283K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$149K
- plus $332K from 9 others
What the payments were for
- Consulting fees$5501%
- Speaking & faculty fees$21,22143%
- Travel & lodging$3,5457%
- Food & beverage$24,24749%
- Education$2210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$12,000
- Jornay PM 20mg capsules (Bottle of 100)$10,380
- SPRAVATO$3,629
- LYBALVI$1,459
- Adzenys XR-ODT$898
- Cotempla XR-ODT$898
- ARISTADA$514
- AUSTEDO$498
- Dyanavel XR$470
- CAPLYTA$355
- Dayvigo$243
- VRAYLAR$240
- Auvelity$231
- NUEDEXTA$126
- Austedo XR$122
- ACTIVA$122
- Azstarys$122
- JORNAY PM$118
- INGREZZA$115
- TRINTELLIX$111
How this compares
$49,784 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lisdexamfetamine Dimesylate | 19 | $2,793 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 25 | $1,012 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Austin
- Arvinder Pal WaliaAustin$2.5M
- Charles NemeroffAustin$429K
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.